Phase
Condition
Stress
Post-traumatic Stress Disorders
Treatment
Prazosin
Propranolol
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Primary Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition criteria Diagnosis of Major Depressive Disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, social anxiety disorder or obsessive-compulsive disorder
Must be able to receive a sertraline dose of 150 mg/day by the second screening visit (Day -15)
Exclusion Criteria
Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days at the end of the study
Diagnosed hypertension (including treated or untreated hypertension), or orthostatic hypotension
Epilepsy or a history of seizures
History of neuroleptic malignant syndrome or serotonin syndrome.
Primary DSM-5 diagnosis of Schizophrenia spectrum and other psychotic disorders, Bipolar and related disorders, Feeding and eating disorders (including anorexia nervosa or bulimia), Neurocognitive disorders (including but not limited to delirium, major or mild neurocognitive disorder due to Alzheimer's, Parkinson's, or traumatic brain injury)
A significant risk of committing violent acts, serious self-harm, or suicide
History of diabetes mellitus (type 1 or type 2)
Subjects with any previous exposure to brexpiprazole, or subjects with chronic use of prazosin or propranolol in the 90 days prior to the screening visit or any use in the 21 days (3 weeks) prior to the screening visit.
Study Design
Connect with a study center
For additional information regarding sites (California, Texas, New Jersey, Minnesota)
Princeton, New Jersey 08540
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.